Brief: Kazia Therapeutics Announces Collaboration And In-Licensing Agreement For First-In-Class PD-L1 Protein Degrader Program
07/10/2025 13:50
Oct 7 (Reuters) - Kazia Therapeutics Ltd KZIA.O: KAZIA THERAPEUTICS ANNOUNCES COLLABORATION AND IN-LICENSING AGREEMENT FOR FIRST-IN-CLASS PD-L1 PROTEIN DEGRADER PROGRAM KAZIA THERAPEUTICS LTD - TO MAKE $1.39 MILLION PAYMENT UNDER AGREEMENT Source text: ID:nPn9N4zB0a Further company coverage: KZIA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kazia Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Bleichroeder Acquisition Corp, Halliburton, BioNTech
U.S. STOCKS ON THE MOVE-Halliburton, BioNTech, Kazia Therapeutics
Kazia drops on $40 mln equity offering to fund breast cancer drug
Kazia slides after breast cancer drug update, equity offering launch
Brief: Kazia Therapeutics Limited Announces Proposed Public Offering